Literature DB >> 26556909

Conflicting Priorities in Social Legislation and Medicine: Gynaeco-oncology Patients and their Right to Participate in Society.

E Simoes1, J Graf2, D Wallwiener3, S Brucker2.   

Abstract

Due to the declining mortality rates, malignant diseases have gained a chronic character for many gynaeco-oncology patients. The patients can expect to participate in social life and to an increasing extent in professional life for longer lengths of time. Promotion of rehabilitation and participation is an issue of the German 9th Social Security Code that explicitly places a focus on women. This is mainly of relevance for tumour patients with regard to assessment of the degree of severe disability, to compensate for disease-induced impairments and the possibilities for improving the participation of the afflicted subjects, especially by means of protective rights in professional life. Indeed, tumour patients do sometimes find themselves confronted with conflicting priorities between the entitlements guaranteed by social legislation and the compensation conferred by the health-care services, which can then be avoided when the facts are sufficiently known. For this purpose, the physician must be fully aware of the legal situation. The present article provides an overview of the procedures and reference points for appraisals. Patients need partners among their responsible physicians to help in the assertion of their claims. From the physician's side it is necessary to classify the reported complaints within the ever increasing knowledge about the direct side effects and the long-term side effects of cancer therapies. Against the background of an often life-long mental stress and the uncertain risk of recurrence, it should also be considered whether the concept of healing probation is in support of the targets of long-term disease management and social reintegration, also in the interest of society in general.

Entities:  

Keywords:  gynaeco-oncology; participation; severe disability; social legislation

Year:  2015        PMID: 26556909      PMCID: PMC4629996          DOI: 10.1055/s-0035-1558055

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  7 in total

1.  Coping, meaning and symptom experience: a narrative approach to the overwhelming impacts of breast cancer in the first year following diagnosis.

Authors:  M Tighe; A Molassiotis; J Morris; J Richardson
Journal:  Eur J Oncol Nurs       Date:  2011-04-20       Impact factor: 2.398

2.  Women's perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study.

Authors:  Fehmidah Munir; Jodie Burrows; Joanna Yarker; Katryna Kalawsky; Manpreet Bains
Journal:  J Clin Nurs       Date:  2010-05       Impact factor: 3.036

3.  Chemotherapy-related cognitive impairment: the breast cancer experience.

Authors:  Jamie S Myers
Journal:  Oncol Nurs Forum       Date:  2012-01       Impact factor: 2.172

4.  Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients.

Authors:  Sanne B Schagen; Enny Das; Ivar Vermeulen
Journal:  Psychooncology       Date:  2011-07-18       Impact factor: 3.894

5.  Late Toxicity of Radiotherapy: A Problem or a Challenge for the Radiation Oncologist?

Authors:  Cordula Petersen; Florian Würschmidt
Journal:  Breast Care (Basel)       Date:  2011-10-31       Impact factor: 2.860

6.  Sense of coherence--stability over time and relation to health, disease, and psychosocial changes in a general population: a longitudinal study.

Authors:  Berit Nilsson; Lars Holmgren; Birgitta Stegmayr; Göran Westman
Journal:  Scand J Public Health       Date:  2003       Impact factor: 3.021

Review 7.  Radiation-induced complications after breast cancer radiation therapy: a pictorial review of multimodality imaging findings.

Authors:  Ann Yi; Hak Hee Kim; Hee Jung Shin; Mi Ock Huh; Seung Do Ahn; Bo Kyeong Seo
Journal:  Korean J Radiol       Date:  2009-08-25       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.